Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE** is a heterocyclic organic compound characterized by fused pyrrole and pyrazine rings with a phenyl group at the sixth position. It belongs to the class of phenylpyrroles and is considered an experimental small molecule. The compound has been investigated for its potential antitumor or anticancer properties and has shown inhibitory activity against cyclin-dependent kinase 5 (CDK5) with an IC50 of approximately 200 nM. Its unique structure makes it a candidate for further exploration in medicinal chemistry as well as organic electronics. There are no approved indications or clinical trials beyond preclinical/experimental stages.[1][2][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-phenyl[5H]pyrrolo[2,3-b]pyrazine.